Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
1-15 of 50130 results
Arix Bioscience raises £100m in IPO
Global healthcare and life science company Arix Bioscience has raised £100m in its Initial Public Offering (IPO) on the main market of the London Stock Exchange.
Production & Manufacturing > Manufacturing > News
Momenta announces FDA warning letter to contracted Glatopa’s fill/finish manufacturer
Momenta Pharmaceuticals has announced that Pfizer, Sandoz’s contracted Glatopa (glatiramer acetate injection) fill/finish manufacturing partner has received a warning letter from the FDA.
Production & Manufacturing > Process & Production > News
Daiichi Sankyo, ArQule’s tivantinib fails to meet primary end point in liver cancer study
By PBR Staff Writer
Daiichi Sankyo and ArQule announced that the tivantinib has failed to meet its primary endpoint in a phase 3 liver cancer study.
Contract Research & Services > Clinical Trials > News
AstraZeneca's Lynparza meets primary endpoint in breast cancer study
By PBR Staff Writer
A phase 3 study of AstraZeneca’s Lynparza (olaparib) met primary endpoint in a phase III trial in BRCA-mutated metastatic breast cancer.
Contract Research & Services > Clinical Trials > News
Valeant gets FDA approval for SILIQ to treat moderate-to-severe plaque psoriasis
The US Food and Drug Administration (FDA) has approved Valeant Pharmaceuticals International's Biologics License Application (BLA) for SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis.
Regulatory Affairs > News
Takeda acquires Ariad Pharmaceuticals
Takeda Pharmaceutical has completed its acquisition of Ariad Pharmaceuticals for $24.00 per share in cash.
Production & Manufacturing > Manufacturing > News
Pfizer's Xeljanz goes head-to-head with AbbVie's Humira in RA study
By PBR Staff Writer
Pfizer said its rheumatoid arthritis drug, Xeljanz, met primary endpoint in combination with methotrexate as compared to AbbVie's drug Humira, although it did not meet the primary endpoint on its own.
Contract Research & Services > Clinical Trials > News
Pfizer, Flynn appeal against UK regulator's £89.4m fine for epilepsy drug price hike
By PBR Staff Writer
Pfizer and Flynn Pharma have appealed against the £89.4m fine imposed by the UK Competition and Markets Authority (CMA) for charging excessive and unfair prices for an anti-epilepsy drug.
Production & Manufacturing > Manufacturing > News
Versant Ventures launches biotechnology firm Jecure Therapeutics
Versant Ventures has launched Jecure Therapeutics, a biotechnology firm focused on the discovery of novel therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis.
Drug Research > Drug Discovery & Development > News
X-Chem, Janssen extend inflammatory disease collaboration
X-Chem has expanded its collaboration with Janssen Biotech for the discovery of new drug leads for inflammatory disease treatment.
Drug Research > Drug Discovery & Development > News
Ardelyx's tenapanor shows significant effect in hyperphosphatemia in phase 3 trial
By PBR Staff Writer
A phase 3 trial evaluating Ardelyx's tenapanor, a novel treatment for hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis, met its primary endpoint of significant difference in serum phosphorus levels.
Contract Research & Services > Clinical Trials > News
ViiV Healthcare unveils positive study results for two-drug regimen for HIV
ViiV Healthcare has announced positive results from its phase 3 program assessing the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir and rilpivirine.
Contract Research & Services > Clinical Trials > News
Horizon Discovery signs master service deal with top three global pharmaceutical firm
Horizon Discovery Group has signed a Master Services Agreement (MSA) with a top three global pharmaceutical company, extending support for their drug discovery and development efforts to its full suite of services.
Contract Research & Services > Contract Services > News
Merck halts clinical trial of Alzheimer's drug
By PBR Staff Writer
Merck said it will halt a phase 2/3 clinical study of an experimental Alzheimer’s drug due to lack of efficacy.
Contract Research & Services > Clinical Trials > News
Novimmune, LegoChem to collaborate on antibody drug conjugate research
Swiss biotech company Novimmune and South Korea based LegoChem Biosciences (LCB) have entered into a research collaboration to evaluate an antibody drug conjugate candidate.
Contract Research & Services > Contract Research > News
1-15 of 50130 results